Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (32)

« Back to Publications

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Turkalj S. et al, (2026), Blood, 147, 613 - 632

Risk Stratification in Older Intensively Treated Patients With AML.

Versluis J. et al, (2024), J Clin Oncol, 42, 4084 - 4094

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.

Freeman SD. et al, (2023), Blood, 142, 1697 - 1707

GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), Cell Stem Cell, 30, 722 - 740.e11

Dysregulation of chromatin via H3K27 methylation underpins differentiation arrest in Isocitrate dehydrogenase-mutant Acute Myeloid Leukaemia

Silveira DRA. et al, (2023)

Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging

Jakobsen NA. et al, (2023)

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).

Sternberg A. et al, (2022), Br J Haematol, 199, 222 - 229

Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.

Symeonidou V. et al, (2022), EJHaem, 3, 794 - 803

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.

Loke J. et al, (2022), Br J Haematol, 196, 368 - 373

Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia

Sweeney C. et al, (2022), BLOOD, 140, 1576 - 1578

Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2-Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study

Chatzikyriakou P. et al, (2022), BLOOD, 140, 3414 - 3415

Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation

Jakobsen NA. et al, (2022), BLOOD, 140, 2227 - 2228

Detecting and quantifying clonal selection in somatic stem cells

Körber V. et al, (2021)

Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.

Cruz Hernandez D. et al, (2020), Blood, 136, 1460 - 1465

Load More